What are the benefit of Omega 3 Fatty acid in patient with Kidney Disease, particularly proteinuria, over risk of economic burden?.
Omega-3 fatty acid supplementation in advanced kidney disease.
Friedman AN1.
Abstract
Long-chain polyunsaturated omega-3 fatty acids (n-3 PUFA), which are obtained primarily from dietary sources such as coldwater fish, have diverse and potent mediating effects on the immune, inflammatory, and metabolic pathways, signal transduction, and cell membrane physiology. N-3 PUFA are increasingly being studied for their clinical benefits in a variety of medical conditions, some of which are relevant to individuals with advanced chronic kidney disease (CKD). These include, among others, renoprotection in IgA nephropathy, cardioprotective effects via a variety of mechanisms including blood pressure and triglyceride reduction, maintenance of dialysis access patency, sparing of inflammation-associated muscle loss, and even mortality. However, further confirmatory work needs to be performed before establishing formal intake recommendations and dosing goals for advanced CKD patients. In the meantime, the current American Heart Association n-3 PUFA intake guidelines can be applied to CKD patients, especially given n-3 PUFA's potential benefits and negligible risk profile. Over time, it will be incumbent upon the nephrology community to more clearly define the utility and optimal dosing of n-3 PUFA in CKD patients with advanced disease via randomized clinical trials.
http://www.ncbi.nlm.nih.gov/pubmed/20701719
Dear Professor Aldallal,
Thank You for your valuable contribution.
With warm regards
Ramesh Sharma Poudel
please find enclosed a paper from Curr Opin Pharmacol. 2013 focusing on inflammation, obesity and CKD and the antiinflammatory effects of n-3 PUFA. Enjoy. best regards, Michaela
Dear Michaela,
Thank your for your valuable contribution. However, attached article emphasized on the reduction of obesity induced CKD through the use of n-3 PUFA. What is the effect of n-3 PUFA in non-obese CKD patients.
Looking forward
With warm regards
Ramesh
Dear Ramesh,
I can only give you some details concerning one kidney disease wich is IgA nephropathy. In this pathology, fatty acid may ameliorate proteinuria (in one of the two papers) but have no effect on renal function.
Best regards
Sébastian
- Hogg et al. - 2006 - Clinical Trial to Evaluate Omega-3 Fatty Acids and Alternate Day Prednisone in Patients with IgA Nephropathy: Report from the Southwest Pediatric Nephrology Study Group
- Chou et al. - 2012 - Omega–3 Fatty Acids Ameliorate Proteinuria but Not Renal Function in IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials
Dear Sebastian,
Thank you for your valuable contribution. I have learn from attached articles.
With warm regards
Ramesh
Omega-3 and renal function in older adults.
Lauretani F1, Maggio M, Pizzarelli F, Michelassi S, Ruggiero C, Ceda GP, Bandinelli S, Ferrucci L.
Abstract
Chronic kidney disease (CKD) is a major public health problem and can result in end-stage renal disease with need for dialysis or transplantation. In Europe up to 12% of the adult population had some renal impairment, while in the United States the end stage of CKD has increased dramatically from 209.000 in 1991 to 472.000 in 2004. Diabetes and hypertension are major causes of kidney pathology. Infection, particularly ascending infection, is more common with increasing age, as both immune function declines and associated pathology predisposing to infection, such as obstructive uropathy, becomes more common. Most pathological changes in the kidney appear to be initiated by oxidative stress, followed by an inflammatory reaction. Oxidative stress results from an imbalance between free radicals and their detoxification by endogenous and exogenous scavengers, including polyunsaturated fatty acids (PUFA). Recent studies showed that PUFA supplementation slowed the rate of loss of renal function in patients with IgA nephropathy. Then, studies of omega-3 supplementation in dialysis patients describe salutary effects on triglyceride levels and dialysis access patency. We examined the relationship between total plasma PUFA levels and change in creatinine clearance over a three-year follow-up in the older persons enrolled in the InCHIANTI study, a population-based epidemiology study conducted in Tuscany, Italy. This study showed that older adults with low total plasma PUFA levels have a greater decline in creatinine clearance over three years of follow-up. These findings suggest that a higher dietary intake of PUFA may be protective against progression to chronic kidney disease.
http://www.ncbi.nlm.nih.gov/pubmed/20041816
Dear Professor Aldallal,
Thank you again for valuable contribution.
With warm regards
Ramesh
What is the cost benefit ratio of using Omega 3 Fatty acid? What are the alternatives of Omega 3 fatty acid in patients with IgA Naphropathy and proteinuria?.